# A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma

> **NCT06097975** · PHASE1 · RECRUITING · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 18 (estimated)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
- **PROCEDURE:** Neurosurgery and intracavitary injection nivolumab and ipililumab
- **DRUG:** Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary

## Key facts

- **NCT ID:** NCT06097975
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06097975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06097975, "A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06097975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*